Status of Malaria Vaccine Introduction—Africa, 2019–2024
- 1Epidemic Intelligence Service, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- 2Global Immunization Division, U.S. Centers for Disease Control and Prevention, Atlanta, Georgia, USA
- 3World Health Organization, Geneva, Switzerland
Abstract
Malaria remains the primary cause of death among children younger than 5 years old in Africa. During 2019–2023, Ghana, Kenya, and Malawi piloted introduction of the first malaria vaccine, RTS,S/AS01, through the Malaria Vaccine Implementation Program. There are two malaria vaccines prequalified by the WHO: RTS,S/AS01 and R21/Matrix-M. The vaccines are recommended for children younger than 5 years old in endemic areas, prioritizing areas of moderate to high transmission. Data on vaccine introduction and doses shipped were obtained from the WHO and the United Nations Children’s Fund. As of December 2024, 17 countries in Africa had introduced the malaria vaccine with support from Gavi, the Vaccine Alliance, and another eight countries had approval for Gavi support. During 2023–2024, a total of 13,250,098 vaccine doses were shipped to countries. The introduction of the malaria vaccine presents an integration opportunity with preventive health services to reduce child morbidity and mortality.
Related
- Preliminary Analysis of the Impact of Malaria Vaccine Introduction on Severe Malaria Incidence in Children Under 5 Years in the Health Districts of Edea, Japoma, and Mbanga (2020–2024)
- Antimicrobial resistance trends and lineage distribution among invasive pneumococcal disease isolates pre- and post-pneumococcal conjugate vaccine introduction, South Africa
- Effect of HPV Vaccine Introduction at 9-10 years: A Randomized Clinical Trial
- Seasonal malaria chemoprevention introduction is associated with sustained reductions in childhood malaria burden in northern Ghana
- Machine learning–based ecological prediction of maternal mortality ratio in malaria-endemic Africa
BibTeX
@article{ly2026status,
title = {{Status of Malaria Vaccine Introduction—Africa, 2019–2024}},
author = {Anh N. Ly and Jenny A. Walldorf and Mary J. Hamel and Eliane Pellaux-Furrer and Rafiq Nii Attoh Okine and Mgaywa G. M. D. Magafu and Jaymin C. Patel and Terri B. Hyde},
journal = {The American Journal of Tropical Medicine and Hygiene},
year = {2026},
month = sep,
doi = {10.4269/ajtmh.26-0338},
url = {https://doi.org/10.4269/ajtmh.26-0338},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Status of Malaria Vaccine Introduction—Africa, 2019–2024
AU - Anh N. Ly
AU - Jenny A. Walldorf
AU - Mary J. Hamel
AU - Eliane Pellaux-Furrer
AU - Rafiq Nii Attoh Okine
AU - Mgaywa G. M. D. Magafu
AU - Jaymin C. Patel
AU - Terri B. Hyde
PY - 2026
DA - 2026/09/17
JO - The American Journal of Tropical Medicine and Hygiene
DO - 10.4269/ajtmh.26-0338
UR - https://doi.org/10.4269/ajtmh.26-0338
AB - Malaria remains the primary cause of death among children younger than 5 years old in Africa. During 2019–2023, Ghana, Kenya, and Malawi piloted introduction of the first malaria vaccine, RTS,S/AS01, through the Malaria Vaccine Implementation Program. There are two malaria vaccines prequalified by the WHO: RTS,S/AS01 and R21/Matrix-M. The vaccines are recommended for children younger than 5 years old in endemic areas, prioritizing areas of moderate to high transmission. Data on vaccine introduction and doses shipped were obtained from the WHO and the United Nations Children’s Fund. As of December 2024, 17 countries in Africa had introduced the malaria vaccine with support from Gavi, the Vaccine Alliance, and another eight countries had approval for Gavi support. During 2023–2024, a total of 13,250,098 vaccine doses were shipped to countries. The introduction of the malaria vaccine presents an integration opportunity with preventive health services to reduce child morbidity and mortality.
SN - 0002-9637
SN - 1476-1645
ER -